RANOLAZINE by Cipla is ranolazine's antianginal effects has not been determined. Approved for chronic angina. First approved in 2019.
Drug data last refreshed 20h ago
ranolazine's antianginal effects has not been determined. Ranolazine has anti-ischemic and antianginal effects that do not depend upon reductions in heart rate or blood pressure. It does not affect the rate-pressure product, a measure of myocardial work, at maximal exercise. Ranolazine at…
Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis
A TSHRN1201 Sub-study-To Evaluate the Effects of add-on Ranolazine on Exercise Tolerance and Angina Frequency
Effect of Ranolazine on Activity Level in Patients With Angina After FFR Based Deferred Intervention (REPTAR)
Effects of Ranolazine on Coronary Microvascular Dysfunction in Patients With Hypertrophic Cardiomyopathy
Effectiveness of Ranolazine on Reducing Chest Pain in Patients With Blockage But no Stents
Worked on RANOLAZINE at Cipla? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.